Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Urology, University of Pittsburgh School of Medicine, 5200 Centre Ave, Suite 209, Pittsburgh, PA 15232, USA. nelsonjb@upmc.edu
Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression. New targets and new therapies are demanded. Through a review of the available literature on endothelin and several preclinical observations, the endothelin axis has emerged as one such target. In phase II and III clinical trials of atrasentan, a potent and selective endothelin receptor A subtype (ET(A)) antagonist, disease progression was delayed in some men. This well tolerated, oral agent may help convert advanced prostate cancer to a more chronic disease. This review will discuss the endothelin axis, preclinical rationale and some of the available clinical trial data on this promising new approach.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on